How much funding has AAVantgarde Bio raised?

AAVantgarde Bio has raised $207.0M in total funding, most recently a Series B round.

Who are AAVantgarde Bio's investors?

AAVantgarde Bio's investors include Atlas Venture, Forbion Capital Partners, Schroders, Longwood Fund, Amgen, Willett Advisors LLC.

When was AAVantgarde Bio founded?

AAVantgarde Bio was founded in 2021.

Where is AAVantgarde Bio headquartered?

AAVantgarde Bio is headquartered in Milan, Italy.

What industry is AAVantgarde Bio in?

AAVantgarde Bio operates in Biotech, Healthcare.

How many employees does AAVantgarde Bio have?

AAVantgarde Bio has 51-200 employees.

AAVantgarde Bio

Next-generation therapies in IRDs

Milan, Italy · Founded 2021 · $207.0M raised

Biotech

Healthcare

Headquarters: Milan
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: aavantgardebio.com
Total Funding: $207.0M
Last Round: $141.0M Series BNov 2025
Rounds: 2

About

AAVantgarde Bio is a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases with high unmet need, focused on Stargardt disease and Usher Syndrome Type 1B. Founded as a spin-off from the Telethon Institute of Genetics and Medicine (TIGEM) in Naples, Italy, and co-founded by Professor Alberto Auricchio, the company is headquartered in Milan, Italy. AAVantgarde has developed a proprietary dual AAV-intein platform capable of delivering large genes that exceed single AAV capsid capacity.

Summary

AAVantgarde Bio is a Biotech company based in Milan, Italy, founded in 2021. It has raised $207.0M in total across 2 rounds, most recently a $141.0M Series B round in Nov 2025. Investors include Atlas Venture, Forbion Capital Partners and Schroders.